A signed written informed consent is required before performing any study-related operations
Age greater than or equal to 18 years old
Histologically or cytologically confirmed locally advanced/metastatic, unresectable non-squamous NSCLC with KRAS p. G12C mutation confirmed by the central lab
No history of systemic anticancer therapy to the local advanced/metastatic disease
Expected survival period greater than or equal to 3 months
Having at least one target lesion according to RECIST 1.1
Eastern Cooperative Oncology Group (ECOG) ≤ 1
You may not be if
Previous (≤2 years) or current solid tumors or hematologic tumors of other pathological types
Carry other driver gene mutations with available target therapy, or carry other KRAS mutations
Subjects with untreated central nervous system (CNS) metastases were excluded;
Uncontrolled pleural effusion, pericardial effusion, and ascites
Subjects with impaired heart function or clinically significant heart disease
Clareo Health | JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
